It is made available under a CC-BY-NC-ND 4.0 International license .

- 1 **Title:** County by county estimation of deaths averted, infections averted, and cost
- 2 savings of overdose prevention health centers in the United States
- 3 Authors: Mike Sportiello, PhD¹, Rohith Palli MD/PhD²
- 4 1. Medical Scientist Training Program at the University of Rochester Medical
- 5 Center. 601 Elmwood Avenue Rochester, NY 14642.
- 6 2. Internal Medicine Residency at the University of Rochester Medical Center. 601
- 7 Elmwood Avenue Rochester, NY 14642.
- 8 Abstract

9 Overdose prevention health centers (OPHCs), also known as overdose 10 prevention centers or safe injection centers, are an evidence-based strategy for people 11 to use drugs in an environment monitored by health care professionals with access to 12 drug use education, sterile supplies, and referral infrastructure to access higher levels of 13 medical and behavioral health resources. Though still illegal under federal law 14 throughout the United States, many legal or guasi-legal (including some in the United 15 States) have operated since the 1980s (Beletsky, Baker et al. 2018). Using CDC 16 overdose deaths and United States Census Bureau population data, we estimate over 17 14,000 deaths could be averted between 2020 and 2022 if 1 out of 20 injections had 18 taken place at an OPHC. At this rate, over 100 HIV transmissions and 57,000 Hepatitis 19 C Virus transmissions would have been averted as well. Almost 20 billion dollars in 20 discounted lifetime costs to treat those infections could have been saved as well. This 21 data supports OPHCs as a viable public health intervention to avert deaths and avoid 22 infections.

It is made available under a CC-BY-NC-ND 4.0 International license .

24 Introduction

25 Overdose prevention health centers (OPHCs), also known as overdose 26 prevention centers or safe injection centers, are an evidence-based strategy for people 27 to use drugs in an environment monitored by health care professionals with access to 28 drug use education, sterile supplies, and referral infrastructure to access higher levels of 29 medical and behavioral health resources. Though still illegal under federal law 30 throughout the United States, many legal or quasi-legal (including some in the United 31 States) have operated since the 1980s (Beletsky, Baker et al. 2018). Since this time, 32 there have been reported overdoses, but no reported deaths in this supervised health 33 care setting, as naloxone, an opioid overdose reversal agent as well as access to 34 respiratory therapy like supplemental oxygen or ventilation is readily available. Other 35 studies have focused on assessing the impact of an OPHC in their community (Irwin, 36 Jozaghi et al. 2016), but no study has analyzed all United States counties and modeled 37 the likely impact. In this analysis, we analyze how many deaths averted, infections 38 averted, and the cost savings accrued had the county adopted OPHCs during this time.

39 Methods

Drug overdose deaths by month per county were accessed from the National Center for Health Statistics from 2020-2022. Population and age data were downloaded from the United States Census Bureau. County names were standardized. For this analysis, we estimated 1.5% of adults were people who injected drugs (PWID) per others' work (Bradley, Hall et al. 2023). For each PWID, we estimated 508.8 injections per year, or just under 1.5 injections per day per other's work (Bradley, Hall et al. 2023).

It is made available under a CC-BY-NC-ND 4.0 International license .

Deaths averted 46

47 Deaths averted was calculated by assuming the total number of injections stayed 48 constant. Secondly, we assumed that deaths cannot occur after an injection in the 49 OPHC, as no overdose death has ever occurred in an OPHC. The *injections that would* 50 occur at OPHC was calculated by modeling 2.5%, 5%, 7.5%, or 10% of injections taking

51 place at the OPHC. This led to the following calculation:

> Injections that would occur at OPHC -* Overdose deaths = Deaths averted *PWID* * *Injections per person*

With the fraction on the left simplifying to the frequency of total injections in the OPHC, 52

53 multiplied by the number of deaths. If all the injections took place at the OPHC, the

54 leftmost fraction would simplify to 1 and all deaths would be averted. If none did, the

55 whole left term would simplify to 0 and no deaths would be averted.

56 HCV transmissions averted

57 Hepatitis C virus (HCV) is a highly transmissible virus in the setting of shared needle use, leading to significant morbidity, mortality, and health expenditures. While 58 59 curative therapy now exists, it is expensive and requires weeks-long adherence which is 60 difficult for many who inject drugs as they are disproportionately housing insecure. 61 Similar to deaths averted, due to the supply of sterile drug use equipment including 62 needles and cottons, transmission of HCV has never been documented at an OPHC. 63 Natural incidence of HCV within PWID varies widely, with studies with varying from 0.51 64 to 47 per 100 person years. For this analysis, we used a lower-end estimate of 10 per 65 100 person years (Gutfraind, Boodram et al. 2015), leading to the following equation: $\frac{Injections that would occur at OPHC}{* HCV incidence} = HCV transmissions averted$

It is made available under a CC-BY-NC-ND 4.0 International license .

66 HIV transmissions averted

Though the vast majority of HIV is not transmitted through injection drug use, it is still a meaningful target of HIV transmission prevention efforts. Others have calculated the incidence of HIV transmission in groups of people who inject drugs, stratifying their use as low, medium, and high risk depending on factors including how often they share needles with people they know and alternatively with strangers (Jarlais, Bobashev et al. 2022). Using these incidences, we calculated HIV transmissions averted with the

73 following equations:

Injections that would occur at OPHCPWID * Injections per person* HIV incidence low risk

= HIV transmissions averted

Injections that would occur at OPHCPWID * Injections per person* HIV incidence medium risk

= HIV transmissions averted

<u>Injections that would occur at OPHC</u> <u>PWID * Injections per person</u> * HIV incidence high risk

= HIV transmissions averted

74 Financial impact

75 Substantial health care dollars are spent treating preventable diseases.

76 Infectious diseases are a particularly good target given how easily they can be

prevented with appropriate education and low-cost materials. Others have estimated the

discounted lifetime cost of an HIV infection to be \$326,500 (Schackman, Fleishman et

al. 2015). We calculated the discounted lifetime cost of an HIV infection with the

80 following equation:

It is made available under a CC-BY-NC-ND 4.0 International license .

326,500 * averted HIV transmission = Discounted cost of an averted HIV infection

- 81 Similar work has been done to calculate the discounted lifetime cost of HCV,
- 82 calculated to \$320,328 (Liu, Barnett et al. 2016).

\$320,328 * averted HCV transmission = Discounted cost of an averted HCV infection

83 Finally, we calculated the total statistical costs of the lives to those who died from

- 84 overdose, using the dollar mount the Federal Emergency Medical Agency \$7,500,000
- 85 uses for their calculations, giving the following equation:

\$7,500,000 * Averted deaths = Statistical costs of deaths averted

86 Results

Deaths averted depends on what percentage of injections occur at the OPHC
(Table 1). At the low end assuming 2.5% of injections occurred at OPHCs (1 injection
out of 50, or one injection every 36 days [50/(508.8/365)]), over 7,000 deaths would
have been averted. At the higher end, almost 29,000 deaths could have been averted.
Figure 1 maps the cumulative deaths averted assuming 5% of injections occurred at an
OPHC.

It is made available under a CC-BY-NC-ND 4.0 International license .

94 Table 1: Summary table of results

Percent injections at	2.5%	5%	7.5%	10%
OPHC				
Deaths averted	7212.43	14424.85	21637.28	28849.70
HCV averted	28677.43	57354.86	86032.29	114709.72
HIV-low averted	57.35	114.71	172.06	229.42
HIV-medium averted	131.92	263.83	395.75	527.66
HIV-high averted	160.59	321.19	481.78	642.37
Discounted lifetime cost of	9.23E+09	1.85E+10	2.77E+10	3.69E+10
infections				
Cost of life	5.41E+10	1.08E+11	1.62E+11	2.16E+11
Total costs	6.33E+10	1.27E+11	1.90E+11	2.53E+11
Total costs (billions)	63.32	126.64	189.97	253.29

95

HCV infections averted range from just under 29,000 to just under 115,000 (Figure 2).
Hundreds of HIV transmissions could have been averted (Figure 3). At least billions of
dollars would have been saved, if not more with higher use, from relatively low rates of
usage of OPHCs.

100 Even if OPHCs were only instituted in the top 50 most populous counties (Table

101 2) or the top 50 deaths per capita (Table 3), a substantial impact would be seen.

It is made available under a CC-BY-NC-ND 4.0 International license .

102 Table 2: Results for 50 most populous counties

Percent injections at OPHC	2.5%	5%	7.5%	10%
Deaths averted	2140.40	4280.80	6421.20	8561.60
HCV averted	8699.02	17398.04	26097.06	34796.08
HIV-low averted	17.40	34.80	52.19	69.59
HIV-medium averted	40.02	80.03	120.05	160.06
HIV-high averted	48.71	97.43	146.14	194.86
Discounted lifetime cost of	2.80E+09	5.60E+09	8.40E+09	1.12E+10
infections				
Cost of life	1.61E+10	3.21E+10	4.82E+10	6.42E+10
Total costs	1.89E+10	3.77E+10	5.66E+10	7.54E+10
Total costs (billions)	18.85	37.71	56.56	75.41

It is made available under a CC-BY-NC-ND 4.0 International license .

104 Table 3: Results for 50 counties with most deaths per capita

Percent injections at OPHC	2.5%	5%	7.5%	10%
Deaths averted	296.45	592.90	889.35	1185.80
HCV averted	350.41	700.83	1051.24	1401.66
HIV-low averted	0.70	1.40	2.10	2.80
HIV-medium averted	1.61	3.22	4.84	6.45
HIV-high averted	1.96	3.92	5.89	7.85
Discounted lifetime cost of infections	1.13E+08	2.26E+08	3.38E+08	4.51E+08
Cost of life	2.22E+09	4.45E+09	6.67E+09	8.89E+09
Total costs	2.34E+09	4.67E+09	7.01E+09	9.34E+09
Total costs (billions)	2.34	4.67	7.01	9.34

105

106 Discussion

107 While it is difficult to estimate the rates of use of OPHCs by those injecting, this 108 study supplies a framework to assist in estimating the impact on deaths, infections, and 109 cost savings. Even at very low rates of use, assuming one out of every 20 injections 110 occurs at OPHCs, tens of thousands of deaths and HCV transmissions are averted. 111 Over 100 HIV transmissions are averted. This study also analyzes the impact on if the 112 50 most populous (Table 2) or the 50 counties with the most deaths (Table 3) were to 113 construct an OPHC, a potentially more realistic and cost-effective strategy. 114 Importantly, this analysis does not include secondary benefits of OPHCs like the 115 association of people voluntarily joining detoxification programs, methadone initiation

It is made available under a CC-BY-NC-ND 4.0 International license .

116	programs, or long-term addiction treatment initiation (Wood, Tyndall et al. 2007). It also
117	doesn't include benefits that education has such as decreasing the rates of needle
118	sharing (Kerr, Tyndall et al. 2005). Lastly, this analysis doesn't include the benefits of
119	secondary social supports unrelated to drug use, including housing support, food
120	support, or other programs.
121	This analysis doesn't include any secondary detriments of OPHCs, though it
122	should be noted that most of those of concern (increase in overdoses, increase in new-
123	onset illicit injection drug use) have not been borne out by studies that that have actually
124	measured these important issues of concern. One important aspect not included in this
125	analysis is the cost to build and maintain these OPHCs, which would require both direct
126	costs of salaries of health and social workers, as well as maintaining these buildings
127	over time.
128	Overall, these data support the broad construction and initiation of OPHCs as a
129	measure to prevent the mortality and morbidity associated with injection drug use.

It is made available under a CC-BY-NC-ND 4.0 International license .

131 References

- 132 Beletsky, L., P. Baker, J. Arredondo, A. Emuka, D. Goodman-Meza, M. E. Medina-Mora, D. Werb,
- 133 P. Davidson, J. J. Amon, S. Strathdee and C. Magis-Rodriguez (2018). "The global health and
- 134 equity imperative for safe consumption facilities." <u>Lancet</u> **392**(10147): 553-554.
- 135 Bradley, H., E. W. Hall, A. Asher, N. W. Furukawa, C. M. Jones, J. Shealey, K. Buchacz, S.
- 136 Handanagic, N. Crepaz and E. S. Rosenberg (2023). "Estimated Number of People Who Inject
- 137 Drugs in the United States." <u>Clin Infect Dis</u> **76**(1): 96-102.
- 138 Gutfraind, A., B. Boodram, N. Prachand, A. Hailegiorgis, H. Dahari and M. E. Major (2015).
- 139 "Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in
- Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections." <u>PLoS One</u> **10**(9):
 e0137993.
- 142 Irwin, A., A. Jozaghi, R. N. Bluthenthal and A. H. Kral (2016). "A Cost-Benefit Analysis of a
- 143 Potential Supervised Injection Facility in San Francisco, California, USA." Journal of Drug Issues
- **144 47**(2).
- 145 Jarlais, D. D., G. Bobashev, J. Feelemyer and C. McKnight (2022). "Modeling HIV transmission
- among persons who inject drugs (PWID) at the "End of the HIV Epidemic" and during the
- 147 COVID-19 pandemic." <u>Drug Alcohol Depend</u> **238**: 109573.
- 148 Kerr, T., M. Tyndall, K. Li, J. Montaner and E. Wood (2005). "Safer injection facility use and
- syringe sharing in injection drug users." <u>Lancet</u> **366**(9482): 316-318.
- 150 Liu, S., P. G. Barnett, M. Holodniy, J. Lo, V. R. Joyce, R. Gidwani, S. M. Asch, D. K. Owens and J. D.
- 151 Goldhaber-Fiebert (2016). "Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus
- 152 Infection in non-VA and VA Populations." <u>MDM Policy Pract</u> 1(1).
- 153 Schackman, B. R., J. A. Fleishman, A. E. Su, B. K. Berkowitz, R. D. Moore, R. P. Walensky, J. E.
- 154 Becker, C. Voss, A. D. Paltiel, M. C. Weinstein, K. A. Freedberg, K. A. Gebo and E. Losina (2015).
- 155 "The lifetime medical cost savings from preventing HIV in the United States." <u>Med Care</u> 53(4):
- 156 293-301.
- 157 Wood, E., M. W. Tyndall, R. Zhang, J. S. Montaner and T. Kerr (2007). "Rate of detoxification
- service use and its impact among a cohort of supervised injecting facility users." <u>Addiction</u>
- **102**(6): 916-919.
- 160

It is made available under a CC-BY-NC-ND 4.0 International license .

Cumulative lives saved




Figure 1: Per county cumulative lives saved assuming 1/20 injections occurred at an OPHC.

It is made available under a CC-BY-NC-ND 4.0 International license .

Cumulative HCV averted




Figure 2: Figure 1: Per county cumulative HCV transmissions averted assuming 1/20 injections occurred at an OPHC.

It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 3: Figure 1: Per county cumulative HIV transmissions averted assuming 1/20 injections occurred at an OPHC according to 3 transmission dynamics: low, medium, or high.